SCHEMBL16619518

SCHEMBL16619518

COC(=O)c1ccc(C#CCC[C@@H](NC(=O)OCc2ccc(OC)cc2)[C@H](O[Si](C)(C)C(C)(C)C)c2ccc(Cl)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP3A4 P08684 6/20 0.37
ALDH1A1 P00352 4/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
CNR2 P34972 1/20 0.35
UTS2R Q9UKP6 5/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
PTPN6 P29350 1/20 0.33
PTPN11 Q06124 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21278203 1.00 NPC1 (0.38) NPC1RAB9ACYP3A4ALDH1A1TSHR
SCHEMBL9933464 0.92 CYP3A4 (0.36) NPC1RAB9ACYP3A4ALDH1A1TSHR
SCHEMBL21278564 0.88 CYP3A4 (0.33) NPC1RAB9ACYP3A4ALDH1A1TSHR
SCHEMBL21278415 0.87 CYP3A4 (0.35) CYP3A4ALDH1A1TSHRTP53KMT2A
SCHEMBL21278207 0.85 ATM (0.41) ALDH1A1TP53MEN1KMT2AATM
SCHEMBL16630235 0.85 ATM (0.41) ALDH1A1TP53MEN1KMT2AATM
SCHEMBL16185906 0.83 ATM (0.42) CYP3A4ALDH1A1TSHRTP53ATM
SCHEMBL11964098 0.82 ATM (0.43) ALDH1A1KMT2AATM
SCHEMBL16619389 0.80 NPC1 (0.34) NPC1RAB9ACYP3A4ALDH1A1TSHR
SCHEMBL21278205 0.80 NPC1 (0.34) NPC1RAB9ACYP3A4ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
EP-3052099-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NPC1 2259/4885RAB9A 1413/4885CYP3A4 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.